CVS Health
CVS stock analysis · Health Care · Health Care Services
As of · fund-implied per-share value
Fund holding value ÷ shares held. Not a live quote; not adjusted for later stock splits.
View SEC fund filing ↗Price × SEC outstanding shares. Shares measured 2026-06-30. Approximate; share and price dates can differ.
View share-count filing ↗DCF value
Equity cash-flow scenario · SEC outstanding shares at 2026-06-30 · -10.3% versus input cap
How this is calculated ↗Reverse DCF
Annual basis · read assumptions below
How this is calculated ↗Relative valuation
52 sector peers · median 25.6×
How this is calculated ↗Historical multiples
7 annual observations · snapshot P/E 74.8× · 293.6% versus history
How this is calculated ↗Free cash flow yield
Annual basis · read assumptions below
How this is calculated ↗ROIC / quality
Normalized tax · financing-capital proxy
How this is calculated ↗Value composite
Annual basis · read assumptions below
How this is calculated ↗12–1 price momentum
Split and corporate-action verification is incomplete for these fund observations. Verified adjusted endpoints are required for 12–1 momentum.
How this is calculated ↗Asset growth
Annual basis · read assumptions below
How this is calculated ↗Net payout yield
Annual basis · read assumptions below
How this is calculated ↗Accrual quality
Annual basis · read assumptions below
How this is calculated ↗Fundamental momentum
Annual basis · read assumptions below
How this is calculated ↗Follow the cash
ANNUAL · USDOperating cash flow and reinvestment over time
Annual USD. Negative bars use a compressed lower scale. Hover or inspect the financial history table for exact values.
Make the assumptions yours
How sensitive is the valuation?
| Return / Growth | 3.0% | 5.0% | 7.0% |
|---|---|---|---|
| 8.0% | $116.38 | $126.98 | $138.38 |
| 10.0% | $85.28 | $92.78 | $100.84 |
| 12.0% | $67.28 | $73.00 | $79.14 |
Annual financial history
Open SEC filings ↗| Fiscal year-end | Revenue | Net income | Operating cash flow | Capital expenditure | Assets |
|---|---|---|---|---|---|
| 2025-12-31 | 402.1B | 1.7B | 10.6B | 2.8B | 253.5B |
| 2024-12-31 | 372.8B | 4.6B | 9.1B | 2.8B | 253.2B |
| 2023-12-31 | 357.8B | 8.4B | 13.4B | 3B | 249.7B |
| 2022-12-31 | 322.5B | 4.3B | 16.2B | 2.7B | 228.3B |
| 2021-12-31 | 292.1B | 8B | 18.3B | 2.5B | 233B |
| 2020-12-31 | 268.7B | 7.2B | 15.9B | 2.4B | 230.7B |
| 2019-12-31 | 256.8B | 6.6B | 12.8B | 2.5B | 222.4B |
| 2018-12-31 | 193.9B | -596M | 8.9B | 2B | 196.5B |
USD, abbreviated. Restated annual history; not a point-in-time backtest. Missing values appear as dashes.
Trace the inputs
MODEL ANNUAL PERIOD| Input | Value | SEC tag / source | Filed |
|---|---|---|---|
| revenue | 402.1B | Revenues | 2026-02-10 |
| netIncome | 1.7B | ProfitLoss Explicit consolidated amount, including the portion attributable to noncontrolling interests. | 2026-02-10 |
| Parent/common earnings proxy | 1.8B | NetIncomeLossAvailableToCommonStockholdersBasic | 2026-02-10 |
| cfo | 10.6B | NetCashProvidedByUsedInOperatingActivities | 2026-02-10 |
| capex | 2.8B | PaymentsToAcquirePropertyPlantAndEquipment | 2026-02-10 |
| operatingIncome | 4.7B | OperatingIncomeLoss | 2026-02-10 |
| assets | 253.5B | Assets | 2026-02-10 |
| equity | 75.4B | StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Explicit consolidated amount, including the portion attributable to noncontrolling interests. | 2026-02-10 |
| Parent book equity proxy | 75.2B | StockholdersEquity | 2026-02-10 |
| debt | 64.6B | LongTermDebtAndCapitalLeaseObligationsCurrent + LongTermDebtAndCapitalLeaseObligations | 2026-02-10 |
| shortDebt | 0 | ShortTermBorrowings | 2026-02-10 |
| cash | 8.5B | CashAndCashEquivalentsAtCarryingValue | 2026-02-10 |
| shares | 1.3B | WeightedAverageNumberOfDilutedSharesOutstanding | 2026-02-10 |
| dividends | 3.4B | PaymentsOfDividends | 2026-02-10 |
| buybacks | 0 | PaymentsForRepurchaseOfCommonStock | 2026-02-10 |
| issuance | 394M | Reviewed manual correction Bounded FY2025-12-31 consolidated financing-statement extraction. Proceeds from exercise of stock options: 394000000 USD [us-gaap:ProceedsFromStockOptionsExercised]. All 10 financing lines reconcile exactly to reported financing cash flow -4940000000 USD. Cash inflows from common shares, employee plans and option exercises are summed once as displayed on the statement; noncash compensation, withholding payments, preferred and noncontrolling interests are excluded. This review applies only to this issuer and fiscal period. Source limitation: the statement also aggregates other financing cash flows (net 0 USD). Their common-equity portion is not separately disclosed here. Issuance is the sum of separately reported common cash-issuance lines, not an independently verified gross total; additional equity flows may be inside those aggregates. | 2026-02-10 |